Synthesis of 6β-D-glucosyl and 6-nitroxy (-)-galanthamine derivatives as acetylcholinesterase inhibitors

Pharmazie

Volumn 62, Issue 6, 2007, Pages 403-405

  Perissutti, E ^a   Fiorino, F ^a   Severino, B ^a   Frecentese, F ^a   Massarelli, P ^b   Nencini, C ^b   Santagada, V ^a   Caliendo, Guiseppe ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4A,5,9,10,11,12 HEXAHYDRO 3 METHOXY 11 METHYL 6 H BENZOFURO [3A,3,2 E,F] [2] BENZAZEPIN 6 (2,3,4,6 TETRA O ACETYL BETA DEXTRO GLUCOPYRANOSIDE; 4A,5,9,10,11,12 HEXAHYDRO 3 METHOXY 11 METHYL 6 H BENZOFURO [3A,3,2 E,F] [2] BENZAZEPIN 6 BETA DEXTRO GLUCOPYRANOSIDE; 4A,5,9,10,11,12 HEXAHYDRO 3 METHOXY 11 METHYL 6 NITROXY 6 H BENZOFURO[3A,3,2 E,F] [2] BENZAZEPIN; CHOLINESTERASE INHIBITOR; GALANTAMINE; UNCLASSIFIED DRUG; DRUG DERIVATIVE; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG SYNTHESIS; ENZYME ACTIVITY; IN VITRO STUDY; NONHUMAN; RAT; ANIMAL; BRAIN; CONFORMATION; DRUG EFFECT; ENZYMOLOGY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SPRAGUE DAWLEY RAT; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; BRAIN; CHOLINESTERASE INHIBITORS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GALANTAMINE; INDICATORS AND REAGENTS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MOLECULAR CONFORMATION; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34250897363     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2007.6.6661     Document Type: Article

References (24)

1. Barrett MP, Walmesley AR, Gould GW (1999) Structure and function of facilitative sugar transporters. Curr Opin Cell Biol 11: 496-502.
2. Bartolucci C, Perola E, Pilmer C, Fels G, Lamba D (2001) Three-dimensional structure of a complex of galanthamine (nivalin) with acetylcholinesterase from Torpedo californica: implications for the design of new anti-Alzheimer drugs. Proteins: Structure, Function and Genetics 42: 182-191.
3. Barton DHR, Kirby GW (1962) Phenol oxidation and biosynthesis. V. Synthesis of galanthamine. J Chem. Soc 806-817.
4. Bartus RT, Dean RL, Beer B, Lippa A (1982) The cholinergic hypothesis of geriatric memory dysfunction S. Science 217: 408-414.
5. Bell GI, Burant CF, Taked J, Gould GW (1993) Structure and function of mammalian facilitative sugar transporters. J Biol Chem 268: 19161-19164.
6. Bores GM, Kosley Jr. RW (1996) Galanthamine derivatives for the treatment of Alzheimer's disease. Drugs Future 21: 621-635.
7. Czollner L, Frantsits W, Kuenburg B, Hedenig U, Frohlich J, Jordis U (1998) New kilogram-synthesis of the anti-Alzheimer drug (-)-galanthamine. Tetrahedron Lett 39: 2087-2088.
8. Dunnett S B, Fibiger H C (1993) Role of forebrain cholinergic systems in learning and memory: Relevance to the cognitive deficits of aging and Alzheimer's dementia. Prog Brain Res 98: 413-420.
9. Ellman GL, Courtney KD, Andres V Jr. Featherstone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7: 88-95.
10. Emson PC, Guevara-Guzman R, Augood SJ, McGowan E, Senaris-Rodriguez R, Norris P, Kendrick KM (1995) Molecular and Cellular Mechanism of Neostriatal Function 299.
11. Greenblatt HM, Kryger G, Lewis T, Silman I, Sussman JL (1999) Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 ANG. resolution. FEBS Lett. 463: 321-326.
12. Greenblatt HM, Guillou C, Guenard D, Argaman A, Botti S, Badet B, Thal C, Silman I, Sussman JL (2004) The complex of a bivalent derivative of galanthamine with torpedo acetylcholinesterase displays drastic deformation of the active-site Gorge: Implications for structure-based drug design. J Am Chem Soc 126: 15405-15411.
13. Han S-Y, Mayer SC, Schweiger EJ, Davis BM, Joullié MM (1991) Synthesis and biological activity of galanthamine derivatives as acetylcholinesterase (AChE) inhibitors. Bioorg Med Chem Lett 1: 579-580.
14. Han SY, Sweeney JE, Backman ES, Schweiger EJ, Forloni G, Coyle JT, Davis DM, Joulliè MM (1992) Chemical and pharmacological characterization of galanthamine, an acetylcholinesterase inhibitor, and its derivatives. A potential application in Alzheimer's disease? Eur J Med Chem 27: 673-687.
15. Kametani T, Yamahi K, Yagi H, Fukumoto K (1969) Studies on the synthesis of heterocyclic compounds. CCCXV. Modified total synthesis of (plus or minus)-galanthamine through phenol oxidation. J Chem Soc (C) 2602-2605.
16. Kametani T, Shishido K, Hayashi E, Seino C, Shibuya S, Fukumoto K (1971a) Alternative total syntheses of (±)-galanthamine. J Org Chem 36: 1295-1297.
17. Kametani T, Seino C, Yamahi K, Shibuya S, Fukumoto K, Satoh F, Hiragi M, Hayasaka T, (1971b) Alternative total syntheses of galanthamine and N-benzylgalanthamine iodide. J Chem Soc (C) 1043-1047.
18. Kuenburg B, Czollner L, Frohlich J, Jordis U (1999) Development of a pilot scale process for the anti-Alzheimer drug (-)-galanthamine using large-scale phenolic oxidative coupling and crystallisation-induced chiral conversion. Org Process Res Dev 3: 425-431.
19. Lewin AH, Szewczyk J, Wilson JW, Carroll FI (2005) Galanthamine analogs: 6H-benzofuro [3a,3,2,-e,f] [1] benzazepine and 6H-benzofuro[3a,3,2-e,f][3] benzazepine. Tetrahedron 61: 7144-7152.
20. Marco-Contelles J, Carreiras MdC, Rodriguez C, Villarroya M, Garcia AG (2006) Synthesis and pharmacology of galantamine. Chem Rev 106: 116-133.
21. Shieh WC, Carlson JA (1994) Asymmetric transformation of either enantiomer of narwedine via total spontaneous resolution process, a concise solution to the synthesis of (-)-galanthamine. J Org Chem 59: 5463-5471.
22. Shimizu K, Tomioko K, Yamada S, Koga K (1977) A biogenetic-type asymmetric synthesis of optically active Amaryllidaceae alkaloids: (+)-and (-)-galanthamine from L-tyrosine. Heterocycles 8: 277-280.
23. Vlakhov R, Krikorian D, Spasov G, Khinova M, Vlakhov I, Parushev S, Snatzke G, Ernst L, Kieslich K, Abraham WR, Sheldrick WS (1989) Synthesis of galanthamine and related alkaloids - new approaches. Tetrahedron 45: 3329-3345.
24. Weinstock M (1997) Possible role of the cholinergic system and disease models. J Neural Transm 49: 93-102.